At the time of writing, Avadel Pharmaceuticals plc [AVDL] stock is trading at $15.0, down -1.06%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AVDL shares have gain 5.63% over the last week, with a monthly amount drifted -4.21%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Avadel Pharmaceuticals plc [NASDAQ: AVDL] stock has seen the most recent analyst activity on September 03, 2025, when Wells Fargo initiated its Equal Weight rating and assigned the stock a price target of $16. On February 11, 2025, Deutsche Bank initiated with a Buy rating and assigned a price target of $12 on the stock. Rodman & Renshaw started tracking the stock assigning a Buy rating and suggested a price target of $27 on June 12, 2024. Oppenheimer reiterated its recommendation of a Outperform and raised its price target to $29 on March 05, 2024. Needham reiterated a Buy rating for this stock on March 05, 2024, and upped its price target to $22. In a note dated March 05, 2024, H.C. Wainwright reiterated a Buy rating on this stock and boosted its target price from $21 to $25.
For the past year, the stock price of Avadel Pharmaceuticals plc fluctuated between $6.38 and $16.66. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. Avadel Pharmaceuticals plc [NASDAQ: AVDL] shares were valued at $15.0 at the most recent close of the market. An investor can expect a potential return of 6.67% based on the average AVDL price forecast.
Analyzing the AVDL fundamentals
According to Avadel Pharmaceuticals plc [NASDAQ:AVDL], the company’s sales were 221.07M for trailing twelve months, which represents an 64.15% jump. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at 0.01%, Pretax Profit Margin comes in at -0.03%, and Net Profit Margin reading is -0.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.04 and Total Capital is 0.02. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.63 points at the first support level, and at 14.26 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.40, and for the 2nd resistance point, it is at 15.79.
Ratios To Look Out For
It is important to note that Avadel Pharmaceuticals plc [NASDAQ:AVDL] has a current ratio of 2.79. In addition, the Quick Ratio stands at 2.38 and the Cash Ratio stands at 1.11. Considering the valuation of this stock, the price to sales ratio is 6.59, the price to book ratio is 16.00.
Transactions by insiders
Recent insider trading involved Palczuk Linda, Director, that happened on Jan 21 ’25 when 5000.0 shares were purchased. Director, Thornton Peter J. completed a deal on Jan 13 ’25 to buy 10000.0 shares. Meanwhile, Director Ende Eric J bought 30000.0 shares on Jan 13 ’25.
